News

Pathos AI raises $237 million at $3B valuation

+3

Tech

Pathos AI raises $237 million at $3B valuation

Derek Foss · 2026-10-23T14:20:22.667Z

Bristol Myers Squibb leading the round suggests they see real potential in AI for Alzheimer's drug work.

7 sourcesUpdated Oct 23, 20261 min read

+3

Sponsored

Pathos AI on October 23, 2026 closed a $237 million Series E led by Bristol Myers Squibb at about $3 billion post-money valuation, up from $1.6 billion in May 2025. The New York company also announced a collaboration with Bristol Myers Squibb and Tempus AI to build AI tools for Alzheimer's and other neurological diseases. Pathos will license neurological-disease data from hundreds of thousands of patients from Tempus under a five-year, $55 million agreement and apply its Foundry platform to generate hypotheses and inform trial design. Bristol Myers receives non-exclusive strategic access to Foundry portfolio-wide plus three-year exclusive rights for neuroscience programs. Pathos said the capital will scale Foundry and advance four clinical assets, with priority on JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate moving toward registrational studies, plus pocenbrodib in mCRPC and RRMM, AstraZeneca-partnered AZD4241, and DO-2. CEO Iker Huerga said the firm is "building a platform to systematically improve the probability of success in drug development" and that Foundry has "fundamentally accelerated" identification of clinical assets. No center- or right-rated coverage appeared in the record; left-rated outlets focused on the raise, valuation, and oncology pipeline.

Sponsored

In this story:

Sponsored

How it spread

Broke Axios · Oct 23, 8:01 AM ETLeft within the hour7 sources +1h on

Claim check

What each side asserts, disputes — or leaves out entirely.

Analyzing the coverage…

Where do you land?

Whose framing of this story rings truest to you?

Sponsored

Coverage

Sponsored

Comments (3)

Ask Genius by OpenServe:

Free account · your comment posts right after signup

Chris Dalton⚡1027m
This kind of cash should let them push their tools further without constant fundraising distractions.
Dana Whitfield⚡727m
A three billion valuation for Pathos feels high given the early stage, though the Tempus tie-up might help.
Derek Foss⚡527m
Bristol Myers Squibb leading the round suggests they see real potential in AI for Alzheimer's drug work.

Sponsored

More on this story

Back to News

Tech

PHP Flaws Prompt Website Shutdowns Worldwide

Several separate flaws threaten WordPress and other PHP-powered websites, including critical PHP vulnerabilities awaiting patches and WordPress core flaws that researchers say can be chained into an unauthenticated server takeover. Risks also include active exploitation of a Bricksforge plugin flaw and malicious code distributed through Rank Math PRO; affected administrators are urged to patch and check for persistent backdoors or unauthorized accounts.

265 sources

Tech

PHP Flaws Prompt Website Shutdowns Amid Attack Surge

Governments and other organizations in Finland, the Netherlands and elsewhere took websites offline after two critical vulnerabilities were found in widely used PHP software. Security experts reported emerging attacks and warned that the flaws could let hackers run code on servers and access data, prompting calls to apply patches immediately or keep affected systems offline until they can be secured.

352 sources

Sponsored

Business

Meta Raises AI Spending, Plans Nonvoting Shares

Morgan Stanley reiterated its Overweight rating on Meta and raised its price target to $820, while noting that Muse’s downloads have not yet translated into strong user retention. StoneX remained cautious ahead of Meta’s third-quarter results, expecting higher expense and capital-spending guidance as AI investment and other costs weigh on the outlook.

291 sources